secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001140361-23-025377
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all patients off oral cysteamine up to 36 months
--------------------------------------------------------------------------------

- All six patients remain off oral cysteamine up to 36 months post gene therapy.
- Durable reduction in leukocyte cystine levels; tissue crystals declined below baseline in first 4 patients.
- Neurocognitive tests (Beery VMI) show improvement/stabilization up to 36 months, suggesting CNS impact.
- No drug-related adverse events or serious adverse events reported to date.
- Positive regulatory feedback from FDA and MHRA to align on registration-enabling trial path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/0001140361-23-025377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/brhc20053135_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-025377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer